Cancers urologiques
— La sélection du Dr Philippe Beuzeboc (Suresnes)

Cancer de la prostate
- 5000 Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC) – Karim Fizazi et al.
  • Vendredi 31 mai
  • 14 h 45 - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
- 5001 Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475) – Christian Carrie et al.
  • Vendredi 31 mai
  • 14 h 45 - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
- 5004 TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC – Marc Pujalte Martin et al.
  • Vendredi 31 mai
  • 14 h 45 - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
- 5005 TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations – Joaquin Mateo et al.
  • Vendredi 31 mai
  • 14 h 45 - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
- LBA2 Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial – Christopher Sweeney et al.
  • Dimanche 2 juin
  • 13 h - Hall B1 - Plenary Session : Genitourinary (Prostate) Cancer

Cancer du rein
- 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study – Brian I. Rini et al.
  • Lundi 3 juin
  • 8 h - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
- 4501 A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx) – Jianjun Gao et al.
  • Lundi 3 juin
  • 8 h - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
- 4508 Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population – Arnaud Mejean et al.
  • Lundi 3 juin
  • 8 h - Arie Crown Theater - Oral Abstract Session : Genitourinary (Prostate) Cancer
Cancers urologiques

— La sélection du Dr Philippe Beuzeboc (Suresnes)

Cancer de la vessie

- 4503 CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma – Jonathan E. Rosenberg et al.
  • Lundi 3 juin
  • 8 h - Arie Crown Theater - Oral Abstract Session : Genitourinary (Nonprostate) Cancer

- 4504 Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182 – Matt D. Galsky et al.
  • Lundi 3 juin
  • 8 h - Arie Crown Theater - Oral Abstract Session : Genitourinary (Nonprostate) Cancer

- LBA4505 EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors – Daniel P. Petrylak et al.
  • Lundi 3 juin
  • 8 h - Arie Crown Theater - Oral Abstract Session : Genitourinary (Nonprostate) Cancer